Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition

Cancer Letters

Volumn 396, Issue , 2017, Pages 117-129

  Halldorsson, Skarphedinn ^a   Rohatgi, Neha ^a   Magnusdottir, Manuela ^a   Choudhary, Kumari Sonal ^a   Gudjonsson, Thorarinn ^a,b   Knutsen, Erik ^c   Barkovskaya, Anna ^d,e   Hilmarsdottir, Bylgja ^d   Perander, Maria ^c   Mælandsmo, Gunhild M ^c,d   Gudmundsson, Steinn ^a   Rolfsson, Óttar ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UNIVERSITY OF TROMSØ   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Breast cancer; EMT; Genome scale models; Metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID TRANSPORTER; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; BREAST EPITHELIUM CELL; CELL SURVIVAL; CITRIC ACID CYCLE; CONTROLLED STUDY; D492 CELL LINE; D492M CELL LINE; DAUGHTER CELL; ENERGY METABOLISM; ENZYMATIC ASSAY; ENZYME MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; ESSENTIAL GENE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GLYCOLYSIS; GROWTH RATE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MESENCHYME CELL; METABOLIC ACTIVATION; METABOLOMICS; MICROARRAY ANALYSIS; OXIDATION KINETICS; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; REGULATOR GENE; RNA SEQUENCE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; BREAST; BREAST TUMOR; EPITHELIUM CELL; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

BREAST; BREAST NEOPLASMS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; METABOLOMICS;

EID: 85016312795     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.03.019     Document Type: Article

References (64)

1. [1] Kalluri, R., EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 119 (2009), 1417–1419.
2. [2] Kalluri, R., Weinberg, R.A., The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119 (2009), 1420–1428.
3. [3] Acloque, H., Adams, M.S., Fishwick, K., Bronner-Fraser, M., Nieto, M.A., Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 119 (2009), 1438–1449.
4. [4] Polyak, K., Weinberg, R.A., Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9 (2009), 265–273.
5. [5] Petersen, O.W., Nielsen, H.L., Gudjonsson, T., Villadsen, R., Rank, F., Niebuhr, E., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Pathol. 162 (2003), 391–402.
6. [6] Barriere, G., Fici, P., Gallerani, G., Fabbri, F., Rigaud, M., Epithelial mesenchymal transition: a double-edged sword. Clin. Transl. Med., 4, 2015, 14.
7. [7] Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T.W., Miriyala, S., et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23 (2013), 316–331.
8. [8] Hanai, J., Doro, N., Sasaki, A.T., Kobayashi, S., Cantley, L.C., Seth, P., et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J. Cell. Physiol. 227 (2012), 1709–1720.
9. [9] Shaul, Y.D., Freinkman, E., Comb, W.C., Cantor, J.R., Tam, W.L., Thiru, P., et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell 158 (2014), 1094–1109.
10. [10] O'Brien, E.J., Monk, J.M., Palsson, B.O., Using genome-scale models to predict biological capabilities. Cell 161 (2015), 971–987.
11. [11] Palsson, B.O., Systems Biology: Constraint-based Reconstruction and Analysis. 2015, Cambridge University Press.
12. [12] Yizhak, K., Le Devedec, S.E., Rogkoti, V.M., Baenke, F., de Boer, V.C., Frezza, C., et al. A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Mol. Syst. Biol., 10, 2014, 744.
13. [13] Choudhary, K.S., Rohatgi, N., Halldorsson, S., Briem, E., Gudjonsson, T., Gudmundsson, S., et al. EGFR signal-network reconstruction demonstrates metabolic crosstalk in EMT. PLoS Comput. Biol., 12, 2016, e1004924.
14. [14] Sigurdsson, V., Hilmarsdottir, B., Sigmundsdottir, H., Fridriksdottir, A.J., Ringner, M., Villadsen, R., et al. Endothelial induced EMT in breast epithelial cells with stem cell properties. PLoS One, 6, 2011, e23833.
15. [15] Paglia, G., Sigurjonsson, O.E., Rolfsson, O., Valgeirsdottir, S., Hansen, M.B., Brynjolfsson, S., et al. Comprehensive metabolomic study of platelets reveals the expression of discrete metabolic phenotypes during storage. Transfusion 54 (2014), 2911–2923.
16. [16] Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A.L., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336 (2012), 1040–1044.
17. [17] Thiele, I., Swainston, N., Fleming, R.M., Hoppe, A., Sahoo, S., Aurich, M.K., et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 31 (2013), 419–425.
18. [18] Vlassis, N., Pacheco, M.P., Sauter, T., Fast reconstruction of compact context-specific metabolic network models. PLoS Comput. Biol., 10, 2014, e1003424.
19. [19] Fell, D.A., Small, J.R., Fat synthesis in adipose tissue. An examination of stoichiometric constraints. Biochem. J. 238 (1986), 781–786.
20. [20] Savinell, J.M., Palsson, B.O., Network analysis of intermediary metabolism using linear optimization. I. Development of mathematical formalism. J. Theor. Biol. 154 (1992), 421–454.
21. [21] Schellenberger, J., Palsson, B.O., Use of randomized sampling for analysis of metabolic networks. J. Biol. Chem. 284 (2009), 5457–5461.
22. [22] Lee, D., Smallbone, K., Dunn, W.B., Murabito, E., Winder, C.L., Kell, D.B., et al. Improving metabolic flux predictions using absolute gene expression data. BMC Syst. Biol., 6, 2012.
23. [23] Fuxe, J., Vincent, T., Garcia de Herreros, A., Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 9 (2010), 2363–2374.
24. [24] Kolesnikoff, N., Attema, J.L., Roslan, S., Bert, A.G., Schwarz, Q.P., Gregory, P.A., et al. Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition. J. Biol. Chem. 289 (2014), 11194–11205.
25. [25] Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123 (2010), 725–731.
26. [26] Mejia, E.M., Hatch, G.M., Mitochondrial phospholipids: role in mitochondrial function. J. Bioenerg. Biomembr. 48 (2016), 99–112.
27. [27] Paradies, G., Paradies, V., De Benedictis, V., Ruggiero, F.M., Petrosillo, G., Functional role of cardiolipin in mitochondrial bioenergetics. Biochim. Biophys. Acta 1837 (2014), 408–417.
28. [28] Buchheit, C.L., Weigel, K.J., Schafer, Z.T., OPINION Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat. Rev. Cancer 14 (2014), 632–641.
29. [29] Hardy, S., El-Assaad, W., Przybytkowski, E., Joly, E., Prentki, M., Langelier, Y., Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J. Biol. Chem. 278 (2003), 31861–31870.
30. [30] Schug, Z.T., Peck, B., Jones, D.T., Zhang, Q., Grosskurth, S., Alam, I.S., et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27 (2015), 57–71.
31. [31] Yizhak, K., Gaude, E., Le Devedec, S., Waldman, Y.Y., Stein, G.Y., van de Water, B., et al. Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. eLife, 3, 2014.
32. [32] Zhao, W., Prijic, S., Urban, B.C., Tisza, M.J., Zuo, Y., Li, L., et al. Candidate antimetastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity. Cancer Res. 76 (2016), 2037–2049.
33. [33] Soda, K., The mechanisms by which polyamines accelerate tumor spread. J. Exp. Clin. Cancer Res., 30, 2011, 95.
34. [34] Guo, J., Li, X., Tan, Z., Lu, W., Yang, G., Guan, F., Alteration of N-glycans and expression of their related glycogenes in the epithelial-mesenchymal transition of HCV29 bladder epithelial cells. Molecules 19 (2014), 20073–20090.
35. [35] Shao, K., Chen, Z.Y., Gautam, S., Deng, N.H., Zhou, Y., Wu, X.Z., Posttranslational modification of E-cadherin by core fucosylation regulates Src activation and induces epithelial-mesenchymal transition-like process in lung cancer cells. Glycobiology 26 (2016), 142–154.
36. [36] Hildebrand, D., Lehle, S., Borst, A., Haferkamp, S., Essmann, F., Schulze-Osthoff, K., α-Fucosidase as a novel convenient biomarker for cellular senescence. Cell Cycle 12 (2013), 1922–1927.
37. [37] McDougall, J.A., Malone, K.E., Daling, J.R., Cushing-Haugen, K.L., Porter, P.L., Li, C.I., Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol. Biomarkers Prev. 22 (2013), 1529–1537.
38. [38] Ahern, T.P., Lash, T.L., Damkier, P., Christiansen, P.M., Cronin-Fenton, D.P., Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 15 (2014), e461–e468.
39. [39] Bellezza, I., Roberti, R., Gatticchi, L., Del Sordo, R., Rambotti, M.G., Marchetti, M.C., et al. A novel role for Tm7sf2 gene in regulating TNFalpha expression. PLoS One, 8, 2013, e68017.
40. [40] Thomson, S., Petti, F., Sujka-Kwok, I., Mercado, P., Bean, J., Monaghan, M., et al. A systems view of epithelial-mesenchymal transition signaling states. Clin. Exp. Metastasis 28 (2011), 137–155.
41. [41] Jerby, L., Wolf, L., Denkert, C., Stein, G.Y., Hilvo, M., Oresic, M., et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 72 (2012), 5712–5720.
42. [42] Kondaveeti, Y., Guttilla Reed, I.K., White, B.A., Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines. Cancer Lett. 364 (2015), 44–58.
43. [43] Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (2014), 178–196.
44. [44] Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
45. [45] Tam, W.L., Lu, H., Buikhuisen, J., Soh, B.S., Lim, E., Reinhardt, F., et al. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24 (2013), 347–364.
46. [46] Badve, S., Dabbs, D.J., Schnitt, S.J., Baehner, F.L., Decker, T., Eusebi, V., et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 24 (2011), 157–167.
47. [47] Gudjonsson, T., Villadsen, R., Nielsen, H.L., Ronnov-Jessen, L., Bissell, M.J., Petersen, O.W., Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 16 (2002), 693–706.
48. [48] Funasaka, T., Hu, H., Yanagawa, T., Hogan, V., Raz, A., Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res. 67 (2007), 4236–4243.
49. [49] Luo, M., Brooks, M., Wicha, M.S., Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr. Pharm. Des. 21 (2015), 1301–1310.
50. [50] Fischer, K.R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S.T., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
51. [51] Yanagisawa, N., Satoh, T., Hana, K., Ichinoe, M., Nakada, N., Endou, H., et al. L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management. Cancer Biomark. 15 (2015), 365–374.
52. [52] Kaira, K., Sunose, Y., Oriuchi, N., Kanai, Y., Takeyoshi, I., CD98 is a promising prognostic biomarker in biliary tract cancer. Hepatobiliary Pancreat. Dis. Int. 13 (2014), 654–657.
53. [53] Isoda, A., Kaira, K., Iwashina, M., Oriuchi, N., Tominaga, H., Nagamori, S., et al. Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci. 105 (2014), 1496–1502.
54. [54] Toyoda, M., Kaira, K., Shino, M., Sakakura, K., Takahashi, K., Takayasu, Y., et al. CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma. Head Neck 37 (2015), 1569–1574.
55. [55] Kaira, K., Toyoda, M., Shino, M., Sakakura, K., Takahashi, K., Tominaga, H., et al. Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathol. Oncol. Res. 19 (2013), 649–656.
56. [56] Kaira, K., Oriuchi, N., Imai, H., Shimizu, K., Yanagitani, N., Sunaga, N., et al. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann. Surg. Oncol. 16 (2009), 3473–3481.
57. [57] Furuya, M., Horiguchi, J., Nakajima, H., Kanai, Y., Oyama, T., Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 103 (2012), 382–389.
58. [58] Janpipatkul, K., Suksen, K., Borwornpinyo, S., Jearawiriyapaisarn, N., Hongeng, S., Piyachaturawat, P., et al. Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration. Cell. Signal. 26 (2014), 1668–1679.
59. [59] Jerby, L., Ruppin, E., Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin. Cancer Res. 18 (2012), 5572–5584.
60. [60] Machado, D., Herrgard, M., Systematic evaluation of methods for integration of transcriptomic data into constraint-based models of metabolism. Plos Comput. Biol., 10, 2014.
61. [61] Yu, M., Lin, G., Arshadi, N., Kalatskaya, I., Xue, B., Haider, S., et al. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol. Cell. Biol. 32 (2012), 3913–3924.
62. [62] Onodera, Y., Nam, J.M., Bissell, M.J., Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J. Clin. Invest. 124 (2014), 367–384.
63. [63] Leon, Z., Garcia-Canaveras, J.C., Donato, M.T., Lahoz, A., Mammalian cell metabolomics: experimental design and sample preparation. Electrophoresis 34 (2013), 2762–2775.
64. [64] Creek, D.J., Nijagal, B., Kim, D.H., Rojas, F., Matthews, K.R., Barrett, M.P., Metabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei. Antimicrob. Agents Chemother. 57 (2013), 2768–2779.